• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

May 3, 2011

View Archived Issues

Actelion Must Pay $547M in Dispute with Asahi Kasei

LONDON – The pressure on Actelion Ltd. is intensifying after a U.S. jury said the company should pay out $547 million in its license dispute with Asahi Kasei Pharma Corp of Tokyo. Read More

Drug Pricing Lessons in the Aftermath of Makena's Approval

Back in June 2006, the FDA launched a formal initiative to get unapproved drugs off the market. That seems like a laudable goal. Over the years there have been some notable cases of unapproved products that resulted in injury or death. A high potency vitamin E injection called E-Ferol used to prevent blindness in premature infants, for instance, resulted in an estimated 40 deaths before it was yanked in 1983. Unapproved formulations of quinine used off-label for leg cramps resulted in 93 deaths before being banned in 2006. But while keeping dangerous medicines from the public is the core of the FDA's mission, some of the negative consequences of that effort have been on display over the last month . . . and served to further tarnish the industry in the eyes of the public. Read More

Other News To Note

Concert Pharmaceuticals Inc., of Lexington, Mass., presented preclinical data showing C-10068 has activity in models of epilepsy, neuroprotection and neuropathic pain. The drug showed anti-convulsant activity in models of both grand mal and partial seizures, and it inhibited hippocampal neurotoxicity and demonstrated neuroprotective effects. The data were presented at the Antiepileptic Drug Trials XI Conference. Read More

Stock Movers

Read More

Clinic Roundup

Agile Therapeutics Inc., of Princeton, N.J., presented and published Phase II data showing that AG200-15 delivers a daily estrogen dose of 30 mcg, is well tolerated and did not cause differences in ovulation in obese vs. nonobese women. The data were presented at the American College of Obstetricians and Gynecologists' 59th Annual Clinical Meeting and published in the journal Hormone Molecular Biology and Clinical Investigation. Read More

Financings Roundup

Marshall Edwards Inc., of San Diego, expects to gross about $4 million through the private placement of common stock and warrants. The company said that about $1.1 million would result from the sale of 835,217 shares of common stock at $1.33 per share and the remaining $2.9 million would be subject to the exercise of one-year series B warrants at their initial exercise price of $1.33 per share and the fulfillment or waiver of certain conditions. Read More

Teva Outbids Valeant for Cephalon in $6.8B Cash Offer

Jerusalem's Teva Pharmaceutical Industries Ltd., announced this morning that it will acquire Frazer, Pa.-based Cephalon Inc. for $6.8 billion in cash, trumping Valeant Pharmaceutical International Inc.'s recent hostile bid of $5.7 billion. Read More

Biotech Ready to Strike Up a Conversation on Dealmaking

SAN FRANCISCO – Chatter in the biotech-sphere over the past year has centered on the current economic environment, health care pricing pressure and the fallout from large-scale acquisitions, all of which have converged to make business development a challenging mission, to say the least. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 5, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe